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Introduction 
The competition between the innovative and generic pharmaceutical companies has 
intensified in the last decades.  Generic medicines have very important role in the 
development of a sustainable and accessible healthcare system. On the other hand, 
innovations should be stimulated to maintain and improve the quality of health care.  Finding 
the balance between pharmacotherapy and pharmacoeconomy is one of the key challenges of 
the pharmaceutical industry and healthcare policies. The inclusion of innovative medicines 
on the positive lists and the influence of the legislation on medicines price control are 
important issues for pharmaceutical companies and patients. 
The Republic of Macedonia has a limited medicines budget, and its healthcare policies aim to 
save on medicines supplies. Nevertheless, the country intends to allow the entry and use of 
innovative medicines, especially for first- and second-line therapy.  
The essential part of the model created by the innovative pharmaceutical industry to enable 
the market exclusivity and increase medicines prices is the system of patent protection. In the 
Republic of Macedonia, the data, market and new indication exclusivity will be implemented 
starting from 2017, and the generic medicines can be registered after the patent protection 
expiry. During the current financial crisis, health authorities decide to promote the use of 
generic medicines rather than more expensive medicines by originators, faced with increased 
costs of their national budgets.  
The existence of multinational innovative companies is difficult in the circumstances of 
limited financial means, low GDP, import-oriented small market, absence of national 
innovative industries and fewer numbers of patients.  The probable solutions might be the 
appropriate price policies that optimise the costs of innovative medicines and their inclusion 
on the positive list, and guarantee their pharmacoeconomic and therapeutic justification. The 
legislation and legislative acts in the Republic of Macedonia are constantly modified due to 
the harmonisation with the European regulation. 
 
Study objective 
We aim to describe the circumstances that lead to innovative medicines’ entry to the market. 
Study methodology 
We analyze the legislation in the Republic of Macedonia and other circumstances that 
influence the innovative medicines’ entry to the market. 
 
Overview of the legislation 
The main legal acts and by-laws that support the methodology for medicines pricing 
(including reference pricing), the establishment of the national reimbursement list and the 
parallel importations have been explained in Table 1.   
 
Table 1: Overview of legal acts and by-laws  
 
Legal acts and by-laws Official 
Gazette / 
year. 
Main characteristics related to medicines prices and 
reimbursement policies 
Law for supplementing 
and amending the Law 
on medicinal products 
and medical devices 
88/2010 Instead of given methology about the price formation, new 
paragraph allows by-laws to treat the matter at technical 
details level. 
Methodology for 
medicines’ single price 
structure  
156/11 
45/12   
Referent pricing: Slovenia, Bulgaria, Netherlands, Poland, 
UK, France, Croatia, Serbia, Greece, Germany, Turkey and 
Russia  
Maximum wholesale medicines price: average value of the 
two lowest comparison wholesale prices from the referent 
countries  
Fees within the wholesale medicine price: wholesale fees, 
custom fees, other import fees 
Retail margin: as a percentage of wholesale prices (28%, 
25%, 20%, up to 1,200 MKD).   
Medicine pricing structure: suggested retail price – the 
same or lower price calculated by this methodology  
The increase of medicines prices - pharmacoeconomic 
study and/or calculations for justification  
Brand medicines or innovative medicines 
Maximum price – average value of the two lowest wholesale 
prices of the brand medicine from the same manufacturer in 
the referent countries  
Pharmacoeconomics indicators 
Law for supplementing 
and amending the Law 
on medicinal products 
and medical devices 
11/2012 Option given for parallel importation of medicines  
Law for supplementing 
and amending the Health 
Insurance Law  
  26/2012 Modification of the mode and the methodology to establish 
the Health Insurance Fund (HIF) medicines reimbursement 
list (Positive list): 
 Ordinance passed by the Government of the Republic of 
Macedonia  
14 expert committees established by the Government of the 
Republic of Macedonia according to the international ATC 
classification, each made from 17 members (14 MDs, 1 MOH 
representative, 1 clinical pharmacologist or pharmacist) with 
one year mandate. 
The committees make the decision based on prior opinion 
given by an appropriate university clinic.  
Ordinance on the mode 
and methodology to 
establish the HIF 
medicines 
reimbursement list  
 
116/ 2012 Medicines on the list   
List A – medicines from primary health care, dispensed at the 
pharmacies contracted by HIF  
List B - medicines from hospital healthcare  
Medicines are grouped according to the ATC classification, 
INN, prescribing regime, indications, application site, 
dispensing of special group medicines, dispensing and use of 
medicines according to indications or remarks about the 
medicines  
Established procedure on the applications for adding or 
removing medicines on the list 
Harmonisation with the HIF financial possibilities.  
Incorporation of the scientific evidence on drug efficacy, 
pharmacotherapeutic and pharmacoeconomic indicators and 
established medicines price.  
Incorporation of the pharmacoeconomic and financial 
analysis, wholesale prices according to DDD and info on 
medicines inclusion on the positive lists in the EU countries 
or other with comparative economic systems.  
List revision at least annually 
Health Insurance Fund 
(HIF) medicines 
reimbursement list 
(Positive list) 
81/2012 
revised text 
Number of amendments and additions 
 medicines dispensed according to the INN and ATC 
classification 
 preferences towards generic medicines  
 small number of innovative medicines 
 Listed indications for reimbursement  
 377 medicines by generic name on the primary 
positive list  
 343 medicines by generic name on the hospital 
positive list  
Rulebook on the criteria 
and procedures to 
establish medicines 
reference prices  
158/ 2009 
138/ 2010  
Referent countries: Slovenia, Croatia, Bulgaria, Serbia  
 Harmonisation of the refence price with the 
purchasing power parity coefficient  
 The price of medicine with no generic competitor 
cannot be higher than 10% of the average comparison 
price  
 The price of medicine with generic competitor cannot 
be higher than 79,23% of the average comparison 
price  
 The option to include the therapeutic equivalent for 
medicines with the same efficiency/safety – 
determination of pharmacological therapeutic groups 
 Reference prices are established on 10 January each 
year. 
 
 
Discussion 
The Law on medicinal products and medical devices from 2007 has been modified to include 
the reference pricing methodology in 2010 and the parallel importation in 2013 (Table 1). 
The by-laws have further explained the medicines pricing and the registration procedure 
(including the 5% VAT).  The reference countries for establishing the unique medicines 
prices include not only the EU countries, but also Serbia, Turkey and the Russian Federation 
(Table 1). Some of them differ significantly from Macedonia in terms of the size of the 
country, its medicines market, or financial parameters.  The reference pricing methodology 
sets very low unique medicines prices, and only medicines of special interest can be up to 
20% higher than the average wholesale prices in the referent countries (Table 1). It lowers 
the companies’ profit, threatens their financial viability, and decreases further the small 
interest of innovative companies for the Macedonian market. Some of them have been 
closing their representative offices in the country.  
As illustrated in Table 1, the reimbursement of medicines is regulated by the Health 
Insurance Law and the Ordinance 116/2012, while the modified methodology for the list has 
been added to the law in 2012. The establishment of expert committees in charge fof the 
positive list is underway. However, the complexity of the procedure delays and hampers the 
process of adding new medicines on the list.   
According to the Health Insurance Law, the insured citizens are entitled to use reimbursed 
medicines on prescriptions, while these medicines are dispensed by pharmacies contracted by 
the HIF (Table 1). The list of expensive medicines are not included in pharmacies’ monthly 
quotas, and are determined by HIF decisions.  
The inclusion procedures for the reimbursement list were defined with the 2012 Ordinance. 
The additions and deletions on the list have to be based on evidence on medicines efficacy, 
pharmacotherapeutic and pharmacoeconomic indicators, and in line with the HIF financial 
possibilities. It also requires data on drug inclusion on the reimbursement lists in the EU or 
countries in the region.  .   
The prescribing of reimbursed medicines by generic name (INN) has been implemented in 
2003 as part of the HIF agreement with the MDs from primary health care. The generic 
prescribing has been one of the successful methodologies to reduce the medicines costs, but   
has also a negative impact on the brand medicines supply and reduces prescribers and 
patients’ choice. The HIF negotiates with the pharmaceutical companies the price alignment 
of brand medicines and pre-determined reference prices of generic medicines to achieve 
lower prices. The new methodology for unique medicines prices and the market competition 
have resulted in savings in the national drug budget. These savings can be used to introduce 
the required innovative medicines on the market.  
The medicines from the hospital positive list are provided through the healthcare institutions, 
and their prices have no impact on the patients, but on the limited hospital budgets.  
The national medicines budget has currently reached 154 million Euros, with 40% for the 
reimbursed medicines, and 60% for commercial ones. Around 3510 medicines are registered 
in the country, which includes 2623 generic (75%), 735 brand (21%) and 152 innovative 
medicines (4%).   The small number of registered innovative and brand medicines is a result 
of the generic prescribing policies, the unique medicines price methodology, the reference 
pricing for reimbursed medicines, the delays, and the strict inclusion rules for the positive 
list. The reimbursement policies are in more favour of generic compared innovative 
medicines. The reference pricing has reduced the prices of most medicines on the 
reimbursement list, but only few innovative medicines can decrease their prices. The 
mandatory generic prescribing and the pharmacies’ obligation to offer the reference priced 
medicine reduce the opportunity to sell the brand medicines.   
The national health authorities consider the positive list to be made according to the WHO 
recommendations for the selection of essential medicines, meeting the population clinical 
needs for most common diseases in the country and according to the financial resources 
available. The last revision of the list has been done based on the HIF Steering Committee 
decision and opinions of the expert committees appointed by the Minister of Health, but 
whose responsibilities ceased with the amendments to the Health Insurance Law in 2012.  
During the active period of this committee (2007-2012) the biggest pressure for inclusion on 
the list has been related to the medicines listed in Table 2. 
 
Table 2: Requests for inclusion of innovative medicines on the reimbursement list 
(2007-2012)  
.   
 
ATC code INN  Name of the 
medicine 
Manufacturer  Registration 
date 
L01XA03 oxaliplatin Eloxatin  
 
Oksaliplatin  
Aventis farma 
Sanofi-Aventis 
Cipla Ltd. 
EBEWE Pharma 
PLIVA LACHEMA a.s.  
13.05.2010 
 
30.06.2009 
29.03.2012 
30.06.2009 
L01XC07 bevacizumab Avastin Hoffman la Roche 28.09.2010 
L01XE01 imatinib   Glivec 
 
Anzovip 
 
 
Imakrebin 
 
 
Plivatinib 
 
NOVARTIS Pharma 
 
ZDRAVLJE A.D. - 
Лесковац,  
 
REMEDICA Ltd - 
Лимасол, Кипар 
 
PLIVA Hrvatska  
25.03.2011 
 
25.12.2012 
 
 
24.01.2013 
 
 
29.11.2012 
L01XE03 erlotinib Tarceva Hoffman la Roche 28.10.2010 
L01XC04 alemtuzimab Mabcampath Boehringer ingelheim 28.10.2010 
B01AX06 rivaroxaban Xarleto BAYER SCHERING 
PHARMA AG 
 
30.12.2008 
 
Only Imatinib was put on the positive list (Official 62/2011), including three more medicines 
with the same generic name later on. Other listed medicines have been rejected on the 
justification for limited national financial means and the existence of therapeutic alternatives. 
All these medicines have all been registered in the country, but their presence on the 
Macedonian market depends largely on their inclusion on the reimbursement list. Since 2012, 
the 14 expert committees have not been appointed yet, so there have been no new 
applications for inclusion on the list.    
The innovative companies reduce the medicines prices according to the methodology for 
unique medicines prices and direct negotiations with the HIF. They estimate that this has led 
to the approximate savings of 20 million Euros, which shall be used to include new 
innovative medicines on the reimbursement list when they have the pharmacoeconomic 
justifications. Additional savings can also be generated by rationalising the positive list, drug 
use in the hospitals and reference prices. The more frequent revision of the positive list (i.e. 
quarterly) can result in the elimination of obsolete medicines and inclusion of innovative 
medicines. 
The financial existence of the innovative companies in the Republic of Macedonia is of 
strategic importance for the country in terms of data provision on innovative medicines, 
presence on the market and post-marketing surveillance.  
The parallel import from 2012 will improve the market offer, but will have a negative impact 
on the financial sustainability of the innovative companies’ representation in Macedonia.  
 
Conclusion and recommendations 
National regulations were put in place to accelerate the access to innovative medicines.  
Simultaneous legal changes and drug pricing policies were designed to support the generic 
market rather than innovations, and control drug budget. This illustrates the national dilemma 
of how to improve access to innovative medicines beneficial for patient health with 
restrictive budget. 
 The Republic of Macedonia has limited drug budget, so its policies are directed 
towards saving of the resources for drug supplies.  
 The country aims to allow the market entrance of innovative medicines and their use, 
especially for first- and second-line treatments in line with its financial possibilities.   
 In recent years, the regulation has been modified to facilitate the market entrance for 
innovative medicines. However, frequent modifications and adjustments according to 
all interested parties have delayed the process of their efficient implementation 
 The generic prescribing and reference pricing have a negative impact on brand 
medicines and limit the choice of prescribers and patients, but save the budget 
resources that can be used to include innovative medicines on the market and the 
reimbursement list.   
 The parallel importation is benefiacial to the market offer, competition and medicines 
prices, but hampers the financial sustainability of the innovative companies’ 
representative offices.  
 The discontinued legal procedured in the last year and the complicated procedures 
delay its completion and the inclusion of innovative medicines on the positive list.  
 The reduction of medicines prices using the methodology of unique prices and 
reference prices for reimbursed medicines can free some resources to be used to 
include new medicines in health care, but lower prices decrease the innovative 
companies’ interest to enter the Macedonian market.  
 Given the limited and insufficient drug budget, savings can be made by rationalising 
the positive list, use of medicines in hospital and introduction of pharmacoeconomic 
aspects in practice, which can be used to include new medicines for patient care.   
 Still, the inclusion of expensive innovative medicines should be based on scientific 
evidence on drug efficiency (first- and second-line therapies), pharmacotherapeutic 
and pharmacoeconomic indicators and HIF financial possibilities.  
 The presence of innovative medicines on the Macedonian market and their inclusion 
on the positive list shall be done according to the experience in the EU and countries 
in the region with comparative economic systems.  
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